Arvinas (ARVN) Invested Capital (2017 - 2026)

Arvinas (ARVN) posted quarterly Invested Capital of $200000.0 for Q3 2023, up 100.0% quarter-over-quarter from $100000.0 in Q2 2023.

Analysis

Arvinas (ARVN) Invested Capital (2017 - 2026) Analysis & Trends

Arvinas' Invested Capital history runs 4 years deep, the most recent figure standing at $200000.0 for Q3 2023.

In Q3 2023, Invested Capital changed N/A year-over-year to $200000.0; the TTM figure through Jun 2024 stood at $200000.0 (changed 0.0% YoY), while the FY2018 annual figure was $154461.0, down 3.02% from the prior year.
Invested Capital for Q3 2023 stood at $200000.0, up from $100000.0 in the prior quarter.
The five-year high for Invested Capital was $200000.0 in Q3 2023, with the low at $71499.0 in Q2 2019.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	33.70 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	7.35 Bn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	6.25 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	19.13 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	1.30 Bn
10	Arvinas	609.77 Mn	41.87 Mn	-	562.70 Mn

Historic Data

Download Data